INTRODUCTION
Urothelial carcinoma of the bladder (UCB) has a wide spectrum of biologic and clinical behavior and is a potentially lethal disease, with over 16,000 deaths annually in the United States. 1 Standard treatment for muscle-invasive UCB includes radical cystectomy with pelvic lymphadenectomy, with or without neoadjuvant chemotherapy. 2 Survival after surgery is associated with overall tumor stage, including depth of invasion and involvement of the lymph nodes with cancer. 3 Predicting patient outcomes after surgery is clinically important, because those with poor predicted survival may be candidates for adjuvant therapy or clinical trials. The current American Joint Commission on Cancer (AJCC) guidelines classify all patients with lymph node (LN)-positive disease as stage IV, with an overall estimated 5-year survival of 15%. 3 However, a more refined consideration of LN-positive patients is needed given evidence that cancer-specific survival (CSS) in this group depends on the degree of LN involvement. [4] [5] [6] Others have observed that survival among patients who had a single LN metastasis was associated with tumor stage, demonstrating that the outcome of patients with LN involvement does not solely depend on the dichotomous presence or absence of LN-positive disease. 7, 8 Nomograms to predict survival after cystectomy have been developed. 4, 5 Although these tools demonstrate reasonable overall accuracy, their adoption has been limited because of the high number of included variables and the burden of using a paper nomogram or computer software. In addition, both nomograms use the AJCC lymph node status, which has demonstrated limited prognostic significance. 6 A simplified prognostic tool that better accounts for the relative influence of tumor stage and LN involvement would be of clinical utility in several ways. First, it could have more widespread clinical use than previously developed nomograms, improving counseling of patients after cystectomy. Second, it could provide a foundation for evaluating and comparing novel molecular and clinical tools designed to improve risk stratification. Finally, improved risk stratification would allow for earlier and more accurate identification of appropriate candidates for clinical trials of adjuvant therapy for aggressive UCB.
We assessed the relative association of tumor stage and LN involvement with the prognosis of patients after cystectomy and lymphadenectomy for UCB in the Surveillance, Epidemiology, and End Results (SEER) cancer database. We then developed a novel prognostic tool for estimating cancer-specific mortality after surgery for this group of patients.
MATERIALS AND METHODS

Patient Identification
Patients who underwent cystectomy with lymphadenectomy between 1988 and 2011 were identified from the population-based SEER database, which comprises 18 cancer registries, in total representing approximately 28% of the United States population. 7 SEER does not contain information on the receipt of chemotherapy (neoadjuvant or adjuvant). The National Cancer Data Base (NCDB) was used as an additional validation cohort and included patients who underwent cystectomy with lymphadenectomy between 2004 and 2013. NCDB does have information on neoadjuvant chemotherapy; however, it only reports overall mortality. Patients with UCB were identified using International Classification of Diseases for Oncology, 3rd edition histologic codes (denoting UCB) 8120 through 8122, 8130, and 8131. Patients who had extranodal metastases at diagnoses (stage M1), those who were missing total LN counts or positive LN counts, and duplicate cases were excluded (Supporting Fig. 1 ; see online supporting information).
Statistical Analysis
The primary outcome was death from bladder cancer in SEER and death from any cause in the NCDB (cancerspecific death is not reported in this database). The covariates examined included year of diagnosis, age at diagnosis, race, sex, tumor grade, tumor stage, LN status, total number of LNs removed, number of positive LNs, and LN density. Tumors were classified according to AJCC guidelines. 3 Because of the relatively small number of nonmuscle-invasive tumors, T1 tumors were combined into a single nonmuscle-invasive group. The tumors were graded using the 2010 World Health Organization criteria as low or high grade. Tumors graded as intermediate by the previous World Health Organization criteria were considered high grade for this analysis. LN density was calculated as the number of positive LNs/total number of LNs removed.
The relative effect of tumor stage in LN-negative versus LN-positive patients was first assessed using Kaplan-Meier analysis stratified by tumor stage and LN status. Adjusted survival analysis was performed using Cox proportional-hazards analysis. Although all 3 LN measures (number of positive LNs, total number of LNs removed, and LN density) were associated with diseasespecific survival, LN density had the strongest association with disease-specific survival and was the only LN variable included in the final analysis. LN density and the number of positive lymph nodes were not included in the same model because of colinearity (r 5 0.58; P < .01).
Prognostic Model Creation
The Cancer of the Bladder Risk Assessment (COBRA) score was created using a method similar to that used for the well-validated Cancer of the Prostate Risk Assessment tools for prostate cancer. [8] [9] [10] The cohort was randomly divided 1:1 into development and validation sets. Initial variables of interest included age, race, sex, grade, tumor stage, and LN density. The variables of interest were initially incorporated into a Cox proportional-hazards model using detailed categories (age group: 50, 51-60, 61-70, 71-80, and 81 [maximum] years; race: white, black, Asian, other; grade: low or high; tumor stage: Ta/Tis, T1, T2, T3, T4; LN density: 0, >0-0.1, >0.1-0.25, >0.25-0.5, and >0.5-1). The log-hazard ratio (HR) parameters (b) estimates from the initial model were used to estimate the relative contribution of each variable in predicting bladder cancer-related death. Variables with small maximum log-HRs were dropped from the model, whereas categories from the remaining variables were condensed (age group: <80, 80 years; tumor stage: T1, T2, T3; LN, 0, >0-0.33, 0.33-0.5, 0.5-1) until a log-HR of approximately 0.5 was associated with 1 point in the model ( Table 1) .
The predictive accuracy of the newly designed COBRA score was evaluated in several ways. In the development data set, Kaplan-Meier survival analysis stratified by COBRA score with the log-rank test for significance was used to visually and statistically confirm that the score appropriately stratified patients by observed survival. Cox proportional-hazards analysis with bootstrap-corrected confidence intervals (CIs) was used to test the performance of the COBRA model as a continuous variable, as an ordinal variable using as score of 0 as the referent, and as a series of pairwise comparisons between each score and the score immediately below it (ie, COBRA scores of 1 vs 0, 2 vs 1, 3 vs 2, etc).
To account for possible over-fitting of the model to the development data set, model calibration was tested in the SEER validation data set. Calibration plots were generated by comparing observed survival in the validation cohort with expected survival based on the development cohort at 2 years and 5 years. Kaplan-Meier survival curves stratified by COBRA level from the SEER and NCDB validation sets were visually compared with the curves generated from the development data set. The increased risk of bladder cancer-related death associated with each point increase in the COBRA score was estimated using Cox analysis with bootstrap-corrected CIs and compared with the estimate generated from the development cohort. The predictive accuracy of the COBRA score was assessed using the Harrell concordance index. The effect of total LN count on the performance of the COBRA score was assessed visually using Kaplan-Meier analysis and statistically using the Harrell concordance index of the Cox model in a population restricted to those with fewer than the median number (<10), with greater than the median number (10) , and in the top quartile (18) of LNs removed in the SEER validation set.
RESULTS
In total, 22,645 patients underwent cystectomy for UCB in the years of interest, and 14,828 underwent surgery with LN dissection and had LN counts available (6210 were excluded for lack of LN dissection, and 1507 were excluded for lack of LN count). Age, race, and sex were similarly distributed between LN-negative (N 5 11,179) and LN-positive (N 5 3649) patients (Table 2) 16-92 months) . The overall median follow-up was 29 months (IQR, 12-71 months) . LN-positive patients were more likely to die of bladder cancer than LNnegative patients, as expected. However, Kaplan-Meier survival analysis demonstrated that those who had organconfined (T2), LN-positive disease had a similar risk of death compared with those who had locally advanced (T3, T4), LN-negative disease (Fig. 1) . Consistent with prior publications, on multivariable analysis, age, sex, Tstage, and LN density were associated with bladder cancer death. 11 This remained true when stratified by extent of LN dissection (Supporting Table 1 ; see online supporting information).
Model Creation
The SEER model development and model validation cohorts each contained 7414 patients and did not differ with respect to the distribution of demographic or pathologic variables (Supporting Table 2 
, and LN density (b 5 1.50). Therefore, race and sex were dropped from the model. The remaining variables (age, tumor stage, and LN density) were condensed so that a coefficient of approximately 0.5 was associated with 1 point. The full score ranged from 0 (lowest risk) to 7 (highest risk), with a maximum of 1 point for age, 3 points for stage, and 3 points for LN density (Table 1) .
Each point increase in the newly developed COBRA score was associated with an HR of 1.61 (95% CI, 1.56-1.65), translating to more than a doubling of the hazard for bladder cancer death for every 2-point increase (Table  3) . A maximum COBRA score of 7 was uncommon (n 5 43) but was associated with a 30-fold increased risk of death over a COBRA score of 0 (HR, 31.35; 95% CI, 20.38-48.24). There was a significant difference in the risk of death associated with each COBRA score level compared with the prior level (ie, 1 vs 0, 2 vs 1) ( Table 3) . The score appropriately stratified the risk of bladder cancer-associated death visually and by log-rank test at 2 and 5 years (Fig. 2) .
Model Validation
The observed 2-year and 5-year survival in the SEER validation cohort for each COBRA score level exhibited good calibration to the expected CSS in the development cohort, with a slightly higher observed mortality rate at 2 years than expected for COBRA levels 2 and 6 ( Figs. 2  and 3 ). The C-indices for the model in the development and validation cohorts were 0.712 and 0.705, respectively. When the population was stratified to patients who had <10, 10, and 18 LNs removed, the C-indices were 0.704, 0.701, and 0.724, respectively, indicating that the model performed best in the cohort with the most LNs removed (Supporting Fig. 2 ; see online supporting information). Validation using the NCDB cohort of 19,362 patients performed comparably with a C-index of 0.68 (using overall survival as the endpoint, because CSS was not available). Each point increase in COBRA score was significantly associated with an HR of 1.46 (95% CI, 1.44-1.47). The score appropriately stratified the risk of overall survival visually and by log-rank test at 5 years (Fig. 4) . The NCDB cohort included patients who received known neoadjuvant chemotherapy (3037 of 19,362 patients; 15.7%). The COBRA score continued to be associated with survival (HR, 1.48; 95% CI, 1.46-1.50) after adjusting for the receipt of neoadjuvant chemotherapy (P < .001).
DISCUSSION
The current results demonstrate that, in a large cohort of patients with UCB who underwent cystectomy, there was a wide range of expected survival. The newly created COBRA score accurately stratifies the risk of diseasespecific and overall mortality in a large cohort LNpositive and LN-negative patients.
The finding that patients with organ-confined, LNpositive UCB have 5-year survival comparable to those with locally advanced, LN-negative disease suggests that there is a similar risk of residual microscopic disease in all of these patients. This is consistent with prior studies demonstrating that, among patients with a single positive LN, local tumor features (ie, T-stage and margin status) were predictors of cancer-specific mortality.
12, 13 Zehnder et al recently demonstrated that patients with LN-positive bladder cancer who declined adjuvant therapy had a 5-year survival rate of 25%, and those who had organconfined, LN-positive disease had an estimated 5-year rate survival of 46%, similar to our current findings. 14 Vieweg and coworkers previously reported that 5-year survival among 42 patients who had N1/N2, organ-confined disease was 60.5% compared with 24.1% among those who had nonorgan-confined N1/N2 disease. 15 Both of those studies used combined institutional cohorts from academic centers, whereas the current study confirmed similar findings in population-based cohorts.
The wide range of prognoses after cystectomy for UCB has been previously recognized and led to the development of several postsurgical prognostic nomograms. 5, [16] [17] [18] Two externally validated models are the International Bladder Cancer Nomogram Consortium (IBCNC) nomogram and the Bladder Cancer Research Consortium (BCRC). 16, 17, 19 The IBCNC nomogram was designed to predict disease recurrence using a large, international, multicenter cohort. This model incorporates 7 different variables into the prediction algorithm, including LN status as negative, positive, or missing. Note that this model includes several variables that may reflect the unique make-up of the cohort, including time to cystectomy, which contributed more points to risk than LN status. The BCRC nomograms were developed from a smaller, US-based, multicenter cohort to predict recurrence, CSS, and overall survival. These nomograms include 8 different variables, and LN status is merely incorporated as N0 through N3 (Table 4) ; also included are lymphovascular invasion, which may not be routinely available from all pathology reports, and prior receipt of adjuvant radiation or chemotherapy, which limits its utility when stratifying patients before potential neoadjuvant therapy. In choosing the measurement of LN disease burden for inclusion in the COBRA score, several possibilities were considered. A prior study by Wright et al using the SEER registry demonstrated that increasing LN density, decreasing total LN count, and increasing number of positive LNs all were associated with bladder cancer mortality after surgery. 11 Our findings confirm this result. LN density alone was included in the COBRA score for several reasons. First, it was decided a priori that LN density and the number of positive LNs would not be included in the same model because of colinearity and toward the goal of model parsimony. LN density was chosen over the number of positive LNs, because LN density was more strongly associated with cancer-specific mortality on univariate analysis. This is consistent with multiple prior singleinstitution studies establishing the prognostic importance of LN density. [20] [21] [22] [23] LN density carries an additional advantage, in that it accounts for both the number of positive LNs and the total count of LNs removed. Total LN count was not included in the final COBRA score because of concern that its inclusion would decrease the generalizability of the score given the known variation in LN yield between both individual surgeons and pathologic methods of LN processing and evaluation. [24] [25] [26] [27] Nevertheless, we observed that COBRA scores accurately stratified patients by CSS at all total LN count thresholds.
There are some limitations that arise from using the SEER data set to develop this model. First, it is subject to errors in coding, data collection, and incomplete data. Such errors are assumed to be random, and a sample of the data from all SEER registries is routinely examined for quality control, but the potential for error remains. The large number of patients included within SEER and the population-based nature of the data set strengthen our model and its applicability to a broad population. Second, no data on comorbid conditions or performance status are available. Other models do exist to predict competing mortality risks in this population. 28, 29 However, cancer recurrence after cystectomy for UCB generally leads to death in a relatively short period; therefore, CSS tracks closely with overall survival in those who have undergone surgery. This is confirmed by the validated performance of COBRA using NCDB, in which only overall survival is available. Third, we included only pure UCB in our analysis. Therefore, this model may not apply to those with squamous cell carcinoma or other variant histology, and this will need to be further validated on additional cohorts. In addition, some pathologic information that may be significant for prognosis was not available, including lymphovascular invasion and extranodal extension.
Although the inclusion of these variables could improve the predictive accuracy of this model, it would make the score unusable for some centers where these data are not routinely reported. Finally, there is no information in SEER on chemotherapy. Evidence suggests that neoadjuvant chemotherapy improves survival in this population, but its use was likely low based on general trends in chemotherapy application both before and after cystectomy in the United States. [30] [31] [32] Increased use of neoadjuvant chemotherapy and adjusted World Health Organization/ International Society of Urological Pathology grading guidelines in 2004 may have contributed to improved stage-for-stage survival in later years. We did observe an 8% lower risk of bladder cancer death in this cohort after 2005, but the COBRA score accurately stratified risk levels both before and after 2005 (Supporting Table 3 ; see online supporting information). We were able to validate the COBRA score in the NCDB cohort, in which patients who receive neoadjuvant chemotherapy can be identified. Because the COBRA score is calculated after cystectomy, we hypothesized that it would likely apply whether or not chemotherapy was received before surgery. When adjusting for the receipt of neoadjuvant chemotherapy in this cohort, the COBRA score indeed did continue to predict survival. A similar limitation applies with regard to adjuvant chemotherapy (AC), which has a reported frequency between 10.4% and 21.3% in patients with locally advanced disease and conflicting data supporting true efficacy. 33 Differential receipt of AC within this group of patients (specifically between those with organ-confined, LN-positive and nonorgan-confined, LN-negative disease) has the potential to confound our results; however factors like age, comorbidity, and insurance status are reported as stronger predictors of AC receipt. 33 Nonetheless, the COBRA score will need to be further validated in other populations.
Moving beyond risk prediction based solely on clinical features is an area of active research for all cancers, and bladder cancer is no exception. To this end, the use of gene expression profiling has been of interest, and recent advances in DNA and RNA sequencing technologies provide the opportunity to incorporate mutation and copy number variation into these panels. Several recent articles have proposed unique gene expression panels designed to improved risk stratification after cystectomy. 34, 35 The predictive ability of both of these panels was improved when they were combined with the nomograms described above. Once it is further externally validated, a potential advantage of the COBRA score is that it could be Original Article
